Item 8.01 Other Information
On September 29, 2021, Allena Pharmaceuticals, Inc. issued a press release to
report that it has dosed the first patient in a second Phase 2a trial of
ALLN-346, a novel, orally-administered, urate-degrading enzyme in development
for the treatment of gout in patients with chronic kidney disease. A copy of the
press release is filed herewith as Exhibit 99.1 to this Report on Form 8-K and
is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit
No. Description
99.1 Press Release of Allena Pharmaceuticals, Inc., dated September 29,
2021.
104 Cover Page Interactive Data File (embedded within the Inline XBRL
document).
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses